Phost’In develops a new class of highly potent anti-cancerous NCEs targeting glycosylation: mechanism of action consists in modifying the cancer cell glycocalyx, which results in inducing an anti-cancer immune response and down modulating cancer invasiveness.
Using its expertise on phosphorus chemistry, 400 molecules have already been synthetized, with a first Drug Candidate PST3.1a qualified on various indications. First-in-Human is planned to be launched by the 12 months, with 3 cohorts of patient from different cancers including our first targeted pathology Glioblastoma (GBM).
Qualified in vivo on subcutaneous and orthotopic mice models, PST3.1a has demonstrated strong antitumoral activity associated with a significant median survival. The compound shows an excellent safety profile, and passes through the blood brain barrier. Furthermore, it inhibits invasiveness and metastatic process.
IP portfolio includes 1 proprietary patent (2016 - covering Lead PST3.1a) and an international exclusive license with sublicensing rights on 2 original academic patents covering the PhostineTM family.
Created in 2014, the company was awarded a special prize in the 2014 ILab competition of the French Research Ministry, and raised €1.8m in equity so far.
Within 4 years, the objective is to boost the value of the platform by licensing PST3.1a and generating new IP (new compounds / new indications).